Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
February 08, 2024 05:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
July 28, 2023 03:00 ET
|
GENENTA SCIENCE SPA
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
June 29, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...